(GOSH) and were already recruited to the Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS), were analysed. Differences in 14 serum biomarkers between disease states (pre-treatment, active, remission) were tested by Kruskal-Wallis analysis of variance. Spearman correlation coefficient and linear regression analyses were performed to determine the association between serum proteins at pretreatment and histopathological severity. Results: There were differences in the distribution of some serum inflammation-related proteins in different disease states in 41 JDM patients. Serum levels of galectin-9 (Gal-9), interferon-gamma inducible protein-10 (IP-10), interferon-gamma inducible T cell alpha chemoattractant-1 (I-TAC), monocyte chemoattractant protein-1 (MCP-1), MCP-2, and tumour necrosis factor receptor type II (TNFRII) reached significantly higher levels in pre-treatment state when compared to the active and remission status. Subsequent analyses focussed on the 11 patients whose serum inflammation-related proteins were analysed before treatment started. None of the 11 patients received corticosteroids or methotrexate at the time of biopsy. Only Gal-9 at pre-treatment was found to be a biomarker that was significantly negatively associated with total biopsy score. As for inflammatory domain of the biopsy scoring tool, Gal-9, IP-10 and IL-10 were significant indicators. Conclusions: Serum Gal-9, IP-10 and IL-10 can predict histopathology in JDM patients. Identifying dysregulated immune pathways and corresponding serum biomarkers of disease severity, including clinical and pathological severity, may provide more information about pathogenesis of JDM and may help develop novel and more targeted therapies for JDM patients, and lead to better treatment outcomes. Background: Magnetic resonance imaging (MRI) can provide a wealth of information about inflammation, erosions, fusion and fat metaplasia in the sacroiliac joints (SIJs) of patients with enthesitis-related arthritis (ERA). However, there is currently a lack of information regarding the natural history of imaging features in ERA patients with axial disease who are treated with biologic therapy. For example, it is unclear whether biologic treatment prevents fusion of the sacroiliac joints, and the relationship between bone marrow oedema and fat metaplasia is uncertain. Aim: To evaluate the effect of treatment on imaging features in young patients with ERA receiving biologic therapy. Methods: A picture archiving and communication system (PACS) search was used to identify all adolescent and young adult patients aged 12-24 with ERA who had undergone at least three MRI scans of the SIJs, over at least a two-year period, with scans before and after anti-TNF treatment. For each scan, inflammation severity was scored on short tau inversion recovery (STIR) images using the Spondyloarthritis Research Consortium of Canada scoring system 1 . Additionally, structural features (specifically erosions, fat metaplasia and fusion) were assessed using a recently proposed structural score
Centre for Medical Imaging, University College London, and 2 Arthritis UK Centre for Adolescent Rheumatology, University College London Background: Magnetic resonance imaging (MRI) can provide a wealth of information about inflammation, erosions, fusion and fat metaplasia in the sacroiliac joints (SIJs) of patients with enthesitis-related arthritis (ERA). However, there is currently a lack of information regarding the natural history of imaging features in ERA patients with axial disease who are treated with biologic therapy. For example, it is unclear whether biologic treatment prevents fusion of the sacroiliac joints, and the relationship between bone marrow oedema and fat metaplasia is uncertain. Aim: To evaluate the effect of treatment on imaging features in young patients with ERA receiving biologic therapy. Methods: A picture archiving and communication system (PACS) search was used to identify all adolescent and young adult patients aged 12-24 with ERA who had undergone at least three MRI scans of the SIJs, over at least a two-year period, with scans before and after anti-TNF treatment. For each scan, inflammation severity was scored on short tau inversion recovery (STIR) images using the Spondyloarthritis Research Consortium of Canada scoring system 1 . Additionally, structural features (specifically erosions, fat metaplasia and fusion) were assessed using a recently proposed structural score 2 . The images were assessed by a consultant musculoskeletal radiologist with over 25 years of experience in musculoskeletal MRI. Pre-and post-treatment scores were compared using a multilevel mixed-effects linear regression model, which accounted for clustering effects. Results: Twenty-two patients were identified for the study. Patients were started on biologics at a mean age of 17y2m, and the mean number of scans per patient was 3.9. Scans were acquired between 3.5 years before starting biologics and 7.8 years after starting biologics. Graphs showing inflammation, erosions, fat metaplasia and fusion over time from biologic start are shown in Figure 1 . Scores for inflammation and erosions were both significantly lower after treatment than before treatment (p < 0.001). Fusion and fat metaplasia scores were significantly higher after treatment (p < 0.001). Discussion: These data suggest that ERA patients undergo a reduction in inflammation but a substantial increase in fusion and fat metaplasia after biologic treatment. Biologic therapy has not prevented fusion in these patients, although it is unclear whether fusion is a consequence of the inflammation itself or biologic treatment. Background: Despite introduction of improved immunosuppressants, treatment of JSLE remains challenging. As dysregulation of B cells is the hallmark of JSLE, clinical research has been focused on B-cell targeted therapies. Rituximab is a B cell depletion therapy directed against the CD20 receptor and studies, in JSLE, have shown improvement of the disease with few adverse events 1 . Metabolomics is involved in identifying and quantifying the biochemical by-products of metabolism. Variations in metabolite concentrations can serve as diagnostic or prognostic biomarkers. Metabolomic analysis in autoimmune diseases has shown that an improved disease score after treatment does not mean that the patient's immune system is corrected to that of healthy controls' 2 . Observing the metabolite prolife of sera from JSLE patients treated with/without Rituximab could provide an objective method to evaluate the effect of treatment. Aims: To compare the metabolite profile of sera of JSLE patients with and without Rituximab treatment to that of paediatric healthy controls. Methods: Serum samples were obtained from children (diagnosed <17 years) with JSLE who either received standard treatment (JSLEÀR, n ¼ 8) or standard treatment plus Rituximab (JSLEþR, n ¼ 3) within the last year and from paediatric healthy controls (n ¼ 9). The samples were run at 310 K on a Bruker 600 MHz AvanceIII with CryoProbe. Resulting 1 H NMR spectra were analysed with Topspin and Chenomx NMR Suite. Results: Global changes in spectra analysed via Principal Component Analysis (PCA) revealed that JSLEþR patients did not exhibit a distinct profile. However one-way ANOVA showed that specific metabolites including Lysine (Fig. 1) were significantly higher (p < 0.05) in JSLEÀR patients compared to healthy controls, and that these levels were lowered to control levels in JSLEþR patients. The proteolipid profiles in JSLE-R sera was similar to controls, but was significantly higher in JSLE+R patients compared to both other groups (Fig. 2) . Conclusions: Variation in metabolic profiles was observed in those patients receiving Rituximab treatment. While many metabolite levels were not affected by Rituximab treatment compared to healthy control or patients not receiving Rituximab treatment, some metabolites varied with diagnosis and treatment. This small study indicates that the effects of Rituximab treatment can be observed in the metabolite levels found in JSLE sera and therefore the environment of immune cells needs further monitoring.
